阿尔茨海默病中的星形胶质细胞生物标志物:系统综述与荟萃分析
该系统综述与荟萃分析检索PubMed和Web of Science,纳入33项研究共3204人,评估血液和脑脊液及PET星形胶质细胞生物标志物在AD中的改变。结果显示AD患者脑脊液GFAP(SMD 0.94,95%CI 0.71-1.18)和YKL-40(SMD 0.76,95%CI 0.63-0.89)及血液S100B(SMD 2.91,95%CI 1.01-4.8)显著升高。作者认为星形胶质细胞生物标志物在AD中持续改变,但应用仍处于早期。
要点
- AD患者脑脊液GFAP和YKL-40水平显著升高。
- AD患者血液S100B水平显著升高。
- 星形胶质细胞生物标志物在AD中持续改变,支持进一步研究。
核心结论
- 星形胶质细胞生物标志物在AD中持续改变,但临床应用仍处于早期阶段。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed和Web of Science数据库,最终纳入33项研究共3204名个体。
主要发现
- AD患者脑脊液GFAP水平显著升高(SMD 0.94,95%CI 0.71-1.18)。
- AD患者脑脊液YKL-40水平显著升高(SMD 0.76,95%CI 0.63-0.89)。
- AD患者血液S100B水平显著升高(SMD 2.91,95%CI 1.01-4.8)。
临床怎么用
- 星形胶质细胞生物标志物可作为AD临床研究框架的候选指标,支持进一步观察性和干预性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a systematic review and meta-analysis to determine whether fluid and imaging astrocyte biomarkers are altered in Alzheimer disease (AD). METHODS: PubMed and Web of Science databases were searched for articles reporting fluid or imaging astrocyte biomarkers in AD. Pooled effect sizes were determined with standardized mean differences (SMDs) using the Hedge G method with random effects to determine biomarker performance. Adapted questions from the Quality Assessment of Diagnostic Accuracy Studies were applied for quality assessment. A protocol for this study has been previously registered in PROSPERO (registration number: CRD42020192304). RESULTS: The initial search identified 1,425 articles. After exclusion criteria were applied, 33 articles (a total of 3,204 individuals) measuring levels of glial fibrillary acidic protein (GFAP), S100B, chitinase-3-like protein 1 (YKL-40), and aquaporin 4 in the blood and CSF, as well as monoamine oxidase-B indexed by PET 11C-deuterium-l-deprenyl, were included. GFAP (SMD 0.94, 95% confidence interval [CI] 0.71-1.18) and YKL-40 (SMD 0.76, 95% CI 0.63-0.89) levels in the CSF and S100B levels in the blood (SMD 2.91, 95% CI 1.01-4.8) were found to be significantly increased in patients with AD. CONCLUSIONS: Despite significant progress, applications of astrocyte biomarkers in AD remain in their early days. This meta-analysis demonstrated that astrocyte biomarkers are consistently altered in AD and supports further investigation for their inclusion in the AD clinical research framework for observational and interventional studies.
引用
- Bellaver B, Ferrari-Souza JP, Uglione da Ros L, et al. Astrocyte Biomarkers in Alzheimer Disease: A Systematic Review and Meta-analysis. Neurology. 2021. PMID: 33952650. doi:10.1212/WNL.0000000000012109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。